News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-197

Hi caketin, forgot bring up your remark ‘it would have taken a very brave soul.....’ comment.

Imho I would think more ‘remiss’ than brave.

We have revenue, revenue that is increasing, the killer blow has been overreaching/overspending by trying to expand everything at once. Surely the R&D cash burn on the vacc s should have been a noteworthy lesson.

Admedus does not have the ‘war chest’ Mercke has!

Here are two companies WITH no revenue yet a sp multiples of Ahz; Rap and Bit!!

Ahz sp could have been what; with the revenue it has, increasing revenue at that and 2 or 3 less CRs because they WERE not overreaching/spending?

All that set up AND then a announcement like the TAVR one would have seen this company far better off than it is.

Any good counter points to that I would appreciate hearing.

Mistake of overreaching has undeniably cost RI dearly, it is to be hoped their is some measure of ‘redemption’ down the track.